Proteasome Inhibitor

5 Drugs classified under this drug class

Proteasome Inhibitor. Bortezomib 3.5 mg.
VIAL (Pwdr. for sol. for IV/SC inj.): 1. Init. dose of Bortezomib is 1.3mg/m², may be admin. IV at a conc. of 1 mg/mL, or SC at a conc. of 2.5 mg/mL. When admin. IV, the drug  is admin. as a 3-5 sec.  bolus IV inj.
Because each route of admin. has a different reconstituted conc., caution should be used when calculat. the volume to be admin. This med. is for IV or SC use only, must not be admin. by any other route. Intrathecal admin. has resulted in death. Dose must be individualized. See lit.
Tmt. of pts. with multiple myeloma.
Tmt. of pts. with mantle cell lymphoma who have received at least one prior ther.
Bortezomib in comb. with rituximab, cyclophosphamide, doxorubicin and prednisone is indic. for the tmt. of adult pts. with prev. untreat. mantle cell lymphoma who are unsuitable for hematopoietic stem cell transplant.
C/I: Hypersens. (not include. local react.) to bortezomib, boron, or mannitol. React. have include. anaphyl. react.
Pts. with acute diffuse infiltrative pulmon. & pericard. dis. Intrathecal admin.

Proteasome Inhibitor. Bortezomib 3.5 mg.
VIAL (Pwdr. for sol. for inj.): 1×3.5 mg. Dosage should be ajust. individ. See lit.
Multiple Myeloma.
Mantle Cell Lymphoma: For the tmt. of pts/ with mantle cell lymphoma who have received at least one prior ther.
Bortezomib in comb. with rituximab, cyclophosphamide, doxorubicin & prednisone is indicated for the tmt. of adult pts. with previous. untreat. mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
C/I: Hypers. to bortezomib, boron or mannitol. Acute diffuse infiltrative pulmon. and pericard. dis. Intrathecal admin.

Proteasome Inhibitor. Bortezomib 3.5 mg.
VIAL (pwdr. for sol. for inj. SC IV):1×3.5mg.
Initial.  is 1.3 mg/m2. may be admin. IV  at a concent.  of 1 mg/mL, or SC at a concent. of 2.5 mg/mL. When admin. IV, Bortezomib is admin. as a 3 -5 second bolus IV inj. Not for intrathecal use. See lit.
Tmt. of pts.  with multip.myeloma. Tmt. of pts. with mantle cell lymphoma who have received at least one prior ther. Bortezomib in comb. with rituximab, cyclophosphamide, doxorubicin and prednisone- tmt. of adult pts. with prev. untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplant.
C/I: Pts. with hypersens. (not includ. local react.), anaphylactic react.  to bortezomib, boron, or mannitol. Pts. with acute diffuse  infiltrative pulmon. and pericard. dis. Intrathecal   admin. (due to fatal events).

Proteasome Inhibitor. Carfilzomib 60 mg/vial.
Vial with pwder. for reconstr. 1X10,30,60 mg: In combination with Lenalidomide and Dexamethasone: admin. this drug 20/27 mg/m² twice/w in 28 d cycles. Discont. after cycle 18. Contin. lenalidomide and dexamethasone until dis. progress. or unaccept. tox. occurs. Combin. with dexamethasone: once/w 20/70 mg/m² regimen or 2/w 20/56 mg/m² regimen. Combin. with Daratumumab (I.V. or S.C.) and Dexamethasone: twice/w 20/56 mg/m² regimen or once/w 20/70 mg/m² regimen. As monotherapy: 20/27 mg/m² twice/w regimen. See full prescr. details.
For adlt. pts. with relapsed or refract. multiple myeloma who have received 1-3 prior lines of ther. in combin. with:
o Lenalidomide and dexamethasone; or
o Dexamethasone; or
o Daratumumab (I.V. or S.C.) and dexamethasone.
-as a sgle. agent for the tmt. of multiple myeloma  pts. who received at least 2 prior ther. incl. bortezomib and an immunomodul. agent and demonstr. dis. progr. on or within 60 days of complet. of the last ther. Approval is based on resp. rate. Clin. benefit, such as improv. in survival or sympt. has not been verified.
C/I: Hypersens.

Proteasome Inhibitor. Bortezomib 3.5 mg.
VIAL (pwdr for sol.): 1. Initial: 1-3 mg/m2 2
x wkly for 2 wks (days 1, 4, 8, and 11)
foll. by 10 day rest period (days 12-21).
This 3 wk. period is a tmt. cycle. At
least 72 hrs. should elapse betw.
consec. doses. See lit.
Myeloma in pts. who have receiv. at least
two prior therapies and have shown
disease progress. on the last ther.
C/I: Hypersens., severe hepat. impair.